Victoria

Sunil is a postdoctoral scientist at the Hudson Institute of Medical Research, Monash University, with a research focus on small RNAs either in gene regulation or their application as synthetic therapeutic agents. In Michael Gantier’s Lab, he is involved in the characterization and development of a novel class of anti-inflammatory oligonucleotide-based therapeutics, one of which is currently in Phase I clinical trial for the treatment of cutaneous lupus. He is the Victorian representative and the current co-chair for the A-RNA EMCR committee.